We present a retrospective analysis of data from 47 patients in this age group diagnosed with ET and enrolled in the 2 consecutive trials, EICESS 92 and EURO-E.W.I.N.G. 99. The median age at diagnosis was 47.7 years (range, 40-68.6 years). Results: The median follow-up was 2.23 years from diagnosis (range, 0.35-12.92 years). 72.3% of patients were found to have localized disease, and 27.7% had primary metastases. Good clinical response to induction therapy was observed in 55%, and 73% of patients showed good histological response. The event-free survival was 0.77 at 1 year and 0.50 at 3 years (n = 44). Conclusion: ET are rare in patients over the age of 40 years. With adequate multimodal therapy, the results in terms of survival are comparable to those in adolescence. Specific age-adapted treatment regimens are not established. Patients should be enrolled in international trials, and if necessary treatment should be adjusted for lower tolerance and co-morbidity.
Introduction
Ewing's tumor (ET) is the second most common osseous tumor of childhood, adolescence, and young adulthood [1, 2] . A new era of ET diagnosis and research was opened in the mid 1990s when the tumor-specific fusion gene EWS/Fli1 was described which allows precise allocation of bone and soft tissue sarcomas [3] to the ET family [4] . The introduction of a multimodal treatment concept consisting of combination chemotherapy and local therapy modalities, including surgery and radiation, achieved 60-70% overall survival in patients with localized disease [2, [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The majority of clinical trials accepted pediatric and adolescent patients, with a median reported age of < 15 years [8, [15] [16] [17] . Information on ET in patients over the age of 40 years is scarce. EICESS 92, a joint trial of the UK Children's Cancer and Leukaemia Group (CCLG) and the German Society of Pediatric Oncology and Hematology (Gesellschaft für Pädiatrische Onkologie und Hämatologie, GPOH) was the first trial open for patients up to age 35, and the international trial EURO-E.W.I.N.G. 99 accepts patients up to age 50 years. Moreover, in both of these studies, the trial center in Münster, Germany, registered and followed up patients > 50 years as non-study patients, and collected relevant data from this group. The present report gives a brief summary of the disease presentation, treatment, and outcome in such patients allocated to an appropriate protocol treatment on an intent-to-treat basis.
Patients and Methods

Patient Characteristics
A total of 47 patients over age 40 with newly diagnosed ET, enrolled between August 1992 and February 2005, were identified among a cohort of 1,720 patients registered at the GPOH Ewing trial center in Münster, Germany. The median age at diagnosis was 47.7 years (range, 40-68.6 years); 20 (42.6%) patients were females, 27 (57.4%), males. The median followup was 2.23 years from diagnosis (range, 0.35-12.92 years) (table 1) .
Treatment
Sixteen patients were treated according to EICESS 92, and 31 patients according to EURO-E.W.I.N.G. 99. Patients gave written informed consent according to institutional and national guidelines. The trials had been approved by the appropriate ethics committees. Sixteen patients qualified as regular study patients of EURO-E.W.I.N.G. 99; all other patients were registered as follow-up patients (table 1). The major reasons for exclusion from regular study patient status were registration or start of treatment > 45 days after biopsy, more than 1 course of other chemotherapy, and age > 50 years (EICESS 92: age > 35 years). Local treatment consisted of radiotherapy and surgery, and was individually planned for each patient. The EICESS 92 protocol accomplished 2 parallel risk-adapted randomized trials. Risk groups were defined by disease stage and tumor volume. Patients with localized tumors < 100 ml were stratified into the standard risk group, those with tumors > 100 ml and/or metastatic disease were allocated to the high risk group. All of the patients received a 4-drug induction treatment of ifosfamide, vincristine, doxorubicin, and actinomycin D (VAIA). For consolidation treatment, either VAIA or VACA (cyclophosphamide replacing ifosfamide) was randomly allocated to standard risk patients. In the high risk arm, VAIA treatment was randomized against EVAIA with the addition of etoposide (E) [18, 19] (fig. 1 ). The EURO-E.W.I.N.G. 99 protocol employs vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) induction chemotherapy, followed by risk-adapted randomized treatment [20] . Patients are stratified into risk groups according to prognostic factors including treatment-independent parameter such as presence and site of metastases, discriminating between pulmonary and extrapulmonary, metastases. In localized disease, the volume of the primary tumor, with a 200-ml cut-off, and/or histological response to induction chemotherapy are critical factors for stratification into the standard or high risk group. Standard risk patients (R 1) are randomized for consolidation treatment with either vincristine, actinomycin D, and ifosfamide (VAI) or vincristine, actinomycin D, and cyclophosphamide (VAC). High risk patients (R 2) are randomized for high dose busulfan/melphalan (Bu-Mel) versus VAI. Patients with extra-pulmonary metastatic disease (R 3) are not randomized, but high dose chemotherapy using Bu-Mel, treosulfan-Mel, or tandem Mel-E followed by autologous stem cell reinfusion or participation in a phase II study is recommended. The EURO-E.W.I.N.G. 99 trial is ongoing and still recruiting patients ( fig. 2 ).
In the EICESS 92 trial, preoperative radiotherapy was frequently used [18] . The EURO-E.W.I.N.G. 99 protocol, however, based on a growing awareness of the prognostic impact of histological response, recommends preoperative radiotherapy only to avoid intralesional surgery, e.g. in the case of poor clinical response to chemotherapy [21] [22] [23] . Surgery was recommended for all patients, if feasible.
Statistical Analysis
Statistical analyses were performed using the SPSS Statistical Package 14.02 (SPSS Inc., Chicago, IL, USA) and SAS 9.1.3. (SAS Institute Inc, Cary, NC, USA). Distributions of survival curves/times (including eventfree survival (EFS) and overall survival (OS)) were estimated by the Kaplan-Meier method. Survival time starts at the day of diagnosis and ends at the date of first event (EFS) or death (OS) or the date of the patient's most recent consultation when all living patients (OS) and patients without event (EFS) were censored. An event was defined as relapse (local or metastatic), progression under therapy (assessable tumor growth), secondary malignancy, or death [24] . Group comparisons were calculated using the log-rank statistic [25] [26] [27] . Multivariate analyses were performed by Cox's proportional hazard method [28] . The significance level was set at p < 0.05 for two-sided test. No alpha corrections were done for multiple testing.
Results
Baseline Characteristics of the Study Population
Patient characteristics are given in 
Clinical and Pathological Response
Clinical response of the primary tumor was assessed after 2 cycles of induction chemotherapy in patients with no primary surgery. Twenty patients were evaluated for response to chemotherapy. Complete or partial response with > 50% reduction in tumor volume was noted in 11 patients (55%). (table 4) . No toxicity-related death was observed.
Treatment Delay
In EICESS 92, treatment delays were reported for 24 cycles, i.e. 5 times due to previous infection, once due to hematotoxicity, 3 times for intercurrent local treatment, once for bladder dysfunction, and once for port-a-cath replacement; in 13 instances the reason was unknown. Treatment delay in EURO-E.W.I.N.G. 99, defined as more than 5 days postponement of a cycle, was reported for 10 [37] , median age 21.5 years (range, 16-55 years)) rather than focusing on patients beyond the typical age. As yet, only 1 single institution report has been published on patients over 40 years. However, this study was a retrospective analysis covering a wide time span of 28 years and 6 different treatment protocols, and evaluated only patients with localized disease [38] . The analysis reported here includes patients with localized and disseminated disease. Besides, patients were recruited within a relatively short period of time (1992-2005), which implies fairly homogeneous diagnostic procedures and treatment. All patients were treated according to the international clinical trials EICESS 92 or EURO-E.W.I.N.G. 99 which were both open for older patients.
In large controlled ET trials, parameters such as primary disseminated disease, poor histological response to induction treatment, large tumor volume and central axial site, and age > 14 years have emerged as major unfavorable factors [39] [40] [41] [42] [43] [44] .
In the present study, 13 out of 47 patients (27.7%) over the age of 40 years had presented with distant metastases at the time at diagnosis, which is comparable to data reported elsewhere [6, 15, 20, 35, [42] [43] [44] [45] [46] [47] [48] [49] . There were also no differences regarding tumor site [2, 6, 50, 51] and histopathological response to induction chemotherapy [33, 35, 52, 53] . However, the group of patients over the age of 40 did show a rather high number of large tumors (71.2% of patients from EURO-E.W.I.N.G. 99 and 50% of patients from EICESS 92). Interestingly, this cohort also included a high proportion of patients with extra-osseous tumors (15 patients, 31.9%). Further investigations are needed to find out whether or not tumor biology is also different in the older age group. It would thus be of major interest to diagnose and treat such patients in controlled studies. Patients younger than 40 years showed a 3-year EFS of 0.57 (95% CI 0.53-0.59) and 3-year OS of 0.68 (95% CI 0.66-0.70). Thus, patients over 40 had a slightly but not significantly lower survival probability (p = 0.1520; p = 0.1314). Chemotherapy-related toxicity is substantial, but predictable and manageable. Most importantly, there were only very few toxicity-related treatment delays, which is in agreement with previously published data [54] . In conclusion, treatment of ET patients over the age of 40 years -similar to that given in the younger age group -should provide for a multimodal treatment concept including combination chemotherapy, complete surgical resection wherever possible, and more radiotherapy. The outcome of our study population is quite comparable to the outcome of pediatric patients and adolescents although the feasibility of applying intense chemotherapy regimes may Histopathological response was determined in 15 patients according to the method of Salzer-Kuntschik et al. [29] . Eleven patients (73%) achieved good histopathological response (< 10% viable tumor cells), 4 patients (27%) were graded as poor responders with more than 10% viable tumor cells (table 6 ). 
Survival
Discussion
Clinical presentation, treatment modalities, and outcome were analyzed in 47 patients over age 40 diagnosed of ET. ET above age 40 are extremely rare, which is why the majority of analyses concerning treatment, prognostic factors, and outcome focus on pediatric patients, adolescents, and young adults [15-17; 30, 31] . There are only few data and reports available on ET in the older age group, and these refer to ages 16-36 [32, 33] , 17-50 [34] [35] [36] , and 16-55 years [37] . Four of these publications (Picci et al. [33] , Siegel et al. [34] , Sinkovics et al. [32] , Klassen et al. [36] ) reported an unfavorable prognosis for adults with non-metastatic ET compared with patients diagnosed in childhood. By contrast, Verill et al. [35] and Fizazi et al. [37] showed outcomes similar to those seen in children in time from diagnosis (years) 14 Pieper/Ranft/Braun-Munzinger/Jürgens/ Paulussen/Dirksen have been restricted in a fair number of patients. Age under these circumstances is not a major poor prognostic feature [35, 37] -the unfavorable prognostic factors in the older age group seem similar to those seen in younger patients [39] [40] [41] [42] [43] [44] . Treatment according to the studies designed for younger patients is feasible and effective. It is therefore recommended to enroll older patients into the ongoing Ewing trials. The trial office offers the support of a multidisciplinary team in guiding a patient through the entire treatment for optimal results. This will also help to augment the knowledge on this age group and eventually develop age-adapted treatment concepts.
